Sativex approved in Wales to treat MS symptoms on NHS
29th August 2014
The cannabinoid Sativex (delta-9-tetrahydrocannabinol/cannabidiol) can now be prescribed on the NHS in Wales to treat symptoms of multiple sclerosis.
The decision taken by the All Wales Medicines Strategy Group was given ministerial approval and supersedes the recommendation made earlier this year, in draft guidance by the National Institute for Health and Care Excellence (NICE), that the drug should not be made available in England and Wales because it is not cost effective.
- CQC annual report: safer management of controlled drugs
- Sativex approved in Wales to treat MS symptoms on NHS
- Ketamine rescheduling consultation
- Levobupivacaine 250mg/200mL epidural infusion bags supply problem
- Dexamfetamine sulfate oral solution now authorized
- Cochrane review: Levetiracetam for neuropathic pain in adults
- Cochrane review: Topical lidocaine for neuropathic pain in adults
- PCF4+ 2013 e-book now half price!
- Class 2 Medicines Recall: Buccolam (midazolam) oromucosal solutions
- Cochrane review: Oxycodone for neuropathic pain and fibromyalgia in adults